Second, not all clinical trials estimated median DOR or median OS for several therapies including dacomitinib for EGFR‐mutated NSCLC, alectinib for ALK‐mutated NSCLC, and larotrectinib for NTRK‐mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.